Incyte's Minjuvi gains Japan approval with 71.4% response
- Incyte received regulatory approval in Japan for its lymphoma treatment combination Minjuvi.
- Following the medical announcement, the Incyte stock price remained unchanged at $98.22.
- The regulatory expansion delivers a new therapeutic option to address unmet needs in advanced blood cancers.
Incyte (NASDAQ:INCY) received Japanese regulatory approval for its cancer drug Minjuvi after clinical trials demonstrated response rates up to 71.4%.
The decision expands treatment options for patients with advanced large B-cell lymphoma who are ineligible for stem cell transplants.
"This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options," said Incyte Biosciences Japan General Manager Yasuyuki Ishida.
Clinical monitoring from the domestic study revealed that the primary adverse side effects included neutropenia and thrombocytopenia.
The newly authorized treatment represents the second regulatory milestone achieved by the therapy within Japan.
The medication previously secured marketing authorization from the health ministry for treating relapsed or refractory follicular lymphoma.
